these families suggested that other phaeochromocytoma susceptibility loci may exist. Glial cell line-derived neurotrophic factor (GDNF) has been recently identified as a natural ligand for RET. Thus, it seems plausible that GDNF is a good candidate gene to play a role in phaeochromocytoma susceptibility. We searched for germline mutations in GDNF in 16 cases of familial phaeochromocytoma (groups A, B and C) and looked for evidence of somatic change in GDNF in 28 sporadic phaeochromocytomas, 12 MEN 2 phaeochromocytomas and five VHL phaeochromocytomas. No GDNF mutations were identified in patients with familial phaeochromocytoma disease, but a c277C→T (R93W) sequence variant was identified in one of 28 sporadic tumours. This candidate mutation was identified in the germline and tumour tissue but was not present in 104 control GDNF alleles. GDNF sequence variants including R93W have been suggested previously to represent low penetrance susceptibility mutations for Hirschsprung disease and the R93W was not identified in 376 control alleles studied by others. These findings suggest that although GDNF mutations do not appear to have a major role in the pathogenesis of familial or sporadic phaeochromocytomas, allelic variation at the GDNF locus may modify phaeochromocytoma susceptibility.
INTRODUCTION
Phaeochromocytoma is a tumour of chromaffin-staining cells which are derived from the embryonic neural crest. Most phaeochromocytomas arise within the adrenal medulla but extra-adrenal phaeochromocytomas (paraganglioma) account for ∼10% of cases. It has been estimated that 10% of patients with phaeochromocytoma have a genetic susceptibility (1) . Predisposition to phaeochromocytoma occurs in three familial cancer syndromes: (i) multiple endocrine neoplasia type 2 (MEN 2) (MIM No 171400) (2); (ii) von Hippel-Lindau (VHL) disease *To whom correspondence should be addressed at the University of Birmingham. Tel: +44 121 627 2642; Fax: +44 121 627 2618; Email: ermaher@hgmp.mrc.ac.uk (MIM No 199300) (3); and (iii) rarely, in neurofibromatosis type 1 (NF1) (MIM No 162200) (4) . In addition, familial phaeochromocytoma (MIM No 171300) alone has also been reported (5) . VHL disease is caused by mutations in the VHL tumour suppressor gene and certain germline missense mutations have been associated with a high risk of phaeochromocytoma in addition to other classical features of VHL disease such as retinal and cerebellar haemangioblastomas and renal cell carcinoma (3, (6) (7) (8) . The three clinical variants of MEN 2 [MEN 2A, MEN 2B and familial medullary thyroid cancer (FMTC)] are caused by gain of function mutations of the RET proto-oncogene which encodes a receptor tyrosine kinase (9) (10) (11) (12) (13) (14) (15) (16) . Most cases of MEN 2A and FMTC have amino acid substitutions at one of five cysteine residues in the extracellular domain (exons 10 and 11) (17) and MEN 2B patients usually have missense mutations in the methionine of codon 918 in the intracellular tyrosine kinase domain (11) (12) (13) . Germline RET mutations may also cause Hirschsprung disease (HSCR) (18) (19) (20) . Recently, glial cell line-derived neurotrophic factor (GDNF) has been shown to be the functional RET ligand (21) (22) (23) (24) and GDNF mutations have been implicated in the pathogenesis of HSCR (25) (26) (27) . Therefore point mutations in GDNF which alter GDNF function in terms of RET binding capacity could be involved in the genesis of MEN 2 related tumours.
Recently, we and others have demonstrated that a proportion of familial phaeochromocytoma is allelic with VHL disease. To date, five of six kindreds with a diagnosis of familial phaeochromocytoma only have been shown to have missense VHL gene mutations (28) (29) (30) . In contrast, somatic RET and VHL gene mutations are infrequent in sporadic phaeochromocytomas (31) (32) . To further investigate the genetic epidemiology and pathogenesis of phaeochromocytoma, we have (i) analysed patients with familial phaeochromocytoma for germline mutations in RET, VHL and GDNF and (ii) screened for somatic GDNF mutations in sporadic, MEN 2 and VHL phaeochromocytomas. Our results suggest that although germline VHL mutations may manifest as familial phaeochromocytoma, germline mutations in VHL and RET are unlikely to account for all cases of phaeochromocytoma susceptibility. In addition, although germline and somatic GDNF mutations do not appear to have a major role in phaeochromocytoma tumorigenesis, they may modify phaeochromocytoma susceptibility.
RESULTS

Identification of germline VHL gene mutations in familial phaeochromocytoma
SSCP analysis revealed variants in: three of the eight families in group A; one of the two individuals in group B; and none of the six families in group C. Genomic sequencing confirmed a germline VHL missense mutation in each of the four cases with an SSCP bandshift: c695G→A, R161Q mutation was identified in two unrelated kindreds and a c451A→G, S80G; and a c712C→T, R167W in the other two families (Fig. 1) . To further increase the efficiency of VHL mutation analysis, sequencing analysis of both strands of the coding region was then performed for all cases in Group A (adrenal phaeochromocytoma kindreds) and of the forward strand in the remaining patients (groups B and C). However this did not reveal any further variants. Human Molecular Genetics, 1997 , Vol. 6, No. 7 1045 To try and exclude linkage to VHL, we performed linkage studies using linked markers (D3S1038 and D3S1317) in five families negative for VHL gene mutations. However, family structures were not optimal and these studies were not informative.
Mutation analysis (SSCP in 28 cases and direct sequencing of the complete coding sequence in 14) of 28 sporadic phaeochromocytomas did not reveal evidence of somatic or germline VHL gene mutations.
Analysis of GDNF
SSCP analysis of GDNF was performed in (i) tumour DNA from 28 sporadic phaeochromocytomas, 12 MEN 2 phaeochromocytomas, and five VHL phaeochromocytomas, (ii) germline DNA from 16 cases of familial phaeochromocytoma (groups A, B and C) described previously and (iii) five cases of familial phaeochromocytoma described previously (28, 31) , four of which have a germline VHL mutation. No abnormality was detected in the cases of familial phaeochromocytoma or MEN 2 and VHL associated phaeochromocytoma tumour tissue. However one of 28 sporadic phaeochromocytomas demonstrated an SSCP band shift and direct sequencing revealed a C to T transition at nt 277 ( Fig. 2 ) which is predicted to produce a non-conservative change, Arg to Trp, at codon 93. Germline DNA from the same individual demonstrated the same sequence variant. The c277C→T sequence change results in the abolition of a HinfI restriction site and 104 GDNF chromosomes from normal control individuals were analysed to determine the frequency of this change. None of the 104 chromosomes analysed had evidence of this change. To assess the sensitivity of GDNF SSCP analysis, we sequenced the GDNF coding region in all 16 cases of familial phaeochromocytoma but did not identify any sequence variants.
Analysis of RET
Germline mutations in exons 10 and 11 were seached for in all 16 kindreds with familial phaeochromocytoma and no sequence changes were identified. In addition three cases (two from Group C and one from Group A) were screened for RET mutations in exons 2, 3 and 5-20 and no abnormality detected. All the results for VHL, GDNF and RET are summarized in Table 1 .
DISCUSSION
The identification of germline VHL mutations in familial phaeochromocytoma kindreds demonstrates the importance of molecular genetic testing for clinical management. Although none of the kindreds investigated had clinical evidence of VHL disease, three of the four kindreds found to have a VHL gene mutation had a mutation (c695G→A, R161Q and c712C→T, R167W) reported previously in classical VHL disease with phaeochromocytoma (3, 33, 34) . Therefore, the identification of these VHL gene mutations enables presymptomatic screening for the onset of VHL disease related tumours. The absence of the other clinical features of VHL disease in these patients may reflect mutation-specific variations in phenotype, variable expression or modifier effects. Allele specific variation in predisposition to phaeochromocytoma has been reported in VHL disease such that missense mutations, most notably at codon 167 (Arg to Trp and Arg to Gln), are more frequent in VHL disease with phaeochromocytoma whereas large deletions, frameshift mutations, and intragenic mutations predicted to produce a truncated protein are less frequent (3, 33, 34) . The identification of novel (i.e. not found in classical VHL families) VHL mutations in familial phaeochromocytoma kindreds suggests that phaeochromocytoma specific mutations do exist. In support of this view is the third mutation we describe, c451A→G, present in a Polish mother and daughter with bilateral phaeochromocytoma. Further support for this concept comes from our group's previous finding of a novel mutation, V84L, (c463G→T) in a Welsh kindred (28) and from the finding of a missense mutation (c775C→G, L188V) in two apparently unrelated German families with familial phaeochromocytoma (29) . These findings suggest that the VHL protein (pVHL) has tissue-specific functions which may be differentially affected by specific missense mutations. Comparison of missense mutations in phaeochromocytoma only families and VHL with phaeochromocytoma kindreds does not, however, demonstrate any clear differences in the sites of mutation. The mutation detection methods used in this study can identify a germline VHL mutation in excess of 80% of VHL families (3, 33) . Together with our previous study (28) , our VHL gene mutation detection rate in familial phaeochromocytoma group A kindreds is 45% (five of 11) and 0% (none of six) in group C patients. Therefore, the involvement of other genes in phaeochromocytoma susceptibility is most likely, particularly in patients with extra-adrenal phaeochromocytoma.
Allele specific variation in predisposition to phaeochromocytoma has also been reported in MEN 2A such that missense mutations at codon 634 are associated with the presence of phaeochromocytoma and hyperparathyroidism (14, 17) . The analysis of RET in our familial phaeochromocytoma kindreds failed to reveal any mutations in exons 10 and 11. This may be explained on several counts. Firstly, our analysis was restricted to the regions mutated in MEN 2 and mutations could occur outside this region (although one Group A and two Group C cases without VHL mutations were screened for mutations in exons 2, 3 and 5-20 of RET and no abnormality was detected). In FMTC, several families with a codon 768 (exon 13) mutation have been described (17) . However gain of function mutations occur at specific sites and the studies we performed should detect mutations in at least 95% of MEN 2 kindreds (17) whereas loss of function RET mutations as described in Hirschsprung disease occur throughout the gene (18) (19) (20) . Extra-adrenal phaeochromocytoma has rarely, if ever, been reported in MEN 2, and it may not be considered surprising that no RET mutations were detected in our group C individuals. The infrequency of somatic VHL and RET mutations in sporadic phaeochromocytomas suggests that additional genes are involved in the genesis of this tumour (31) . We then proceeded to analyse glial cell line-derived neurotrophic factor (GDNF) as a candidate gene for familial and sporadic phaeochromocytoma. GDNF has been identified recently as a ligand for RET (21) (22) (23) (24) . According to the proposed model of action, GDNF Receptoralpha (GDNFR-α), a novel glycolipid anchored membrane protein, binds GDNF and this complex is subsequently recognised by RET. The formation of a stable complex between these three entities results in tyrosine phosphorylation of RET which then leads to cell signalling. Therefore, by analogy with RET mutations in MEN 2, gain of function mutations in GDNF could predispose to phaeochromocytoma. However, we were unable to identify mutations in GDNF, either germline in cases of familial phaeochromocytoma, or somatic in most sporadic and syndromic phaeochromocytomas. To assess the sensitivity of our SSCP analysis we sequenced GDNF in 16 cases but did not identify any variants not detected by SSCP. Dahia et al. (33) have also reported no GDNF mutations in 22 sporadic phaeochromocytomas analysed. Nevertheless, we did identify a GDNF sequence variant (R93W) in the germline of an individual with a sporadic phaeochromocytoma. This variant could represent a pathogenic mutation or a polymorphism. Evidence against a polymorphism is that this non-conservative substitution occurs at a residue which is conserved in all other species (mouse and rat) studied to date. Furthermore, two groups have reported finding the same GDNF R93W substitution in two families with HSCR but not in 376 control alleles (26, 27) . To date, four of five HSCR patients reported with a GDNF sequence variant have had an additional aetiology for HSCR (e.g. RET mutation) and it has been proposed that GDNF variants such as the R93W substitution act as modifiers which modulate the disease phenotype by interacting with other major susceptibility loci such as RET. However, Ivanchuk et al. (25) reported a de novo GDNF mutation (T154S) in an isolated case of HSCR. Our results suggest that GDNF alleles such as R93W could also function as low-penetrance susceptibility mutations for phaeochromocytoma. The suggestion that a single GDNF mutation may predispose to both phaeochromocytoma and HSCR susceptibility is intriguing. The spectrum of RET mutations in MEN 2 and HSCR individuals differ. However rarely, HSCR and MEN 2 may be found in the same family suggesting a shared susceptibility factor. Our results suggest that additional phaeochromocytoma susceptibility genes remain to be identified. Candidate genes would include GDNFR-α. Loss of heterozygosity (LOH) studies of phaeochromocytomas from sporadic and syndromic cases have indicated loss of 1p, suggesting that this region may harbour a tumour suppressor gene or genes whose inactivation may be important in the development of this tumour (34, 35) .
This study represents the largest molecular genetic investigation into the genetic susceptibility to phaeochromocytoma. We conclude that: in some cases familial phaeochromocytoma is allelic with VHL disease; MEN 2 associated RET mutations do not account for cases of familial phaeochromocytoma; and GDNF does not have a major role in the genetic susceptibility to phaeochromocytoma; however GDNF allelic variants may influence phaeochromocytoma susceptibility. Nevertheless, our results suggest that further susceptibility loci remain to be identified.
MATERIALS AND METHODS
Patients
VHL analysis. All subjects analysed had no clinical evidence or family history of MEN 2, VHL, or NF1. The patients were divided into three groups according to clinical criteria: group A, eight kindreds with familial phaeochromocytoma; group B, two individuals with bilateral phaeochromocytoma; and group C, six individuals with either multiple extra-adrenal phaeochromocytoma or adrenal phaeochromocytoma and a family history of neuroectodermal tumours.
GDNF analysis. Germline GDNF was analysed in patients from the above three groups in whom no germline VHL mutations were detected. In addition, tumour DNA samples from 28 sporadic phaeochromocytomas, 12 MEN 2 phaeochromocytomas and five VHL phaeochromocytomas were screened for somatic mutations in GDNF (Table 2 ).
Molecular analysis
Investigation of germline VHL mutations in familial phaeochromocytoma. The method is as described in Crossey et al. (33) but with some modifications. The nucleotide sequence 677-1036 was amplified using one primer pair (annealing temperature 63_C) with the following sequence: F:5′ CACACTGCCACA-TACATGCACTC 3′; and R: 5′ TGCCCCTAAACATCA-CAATGCCTA 3′. Each reaction required 0.8 µM of primer and a 'hot' start. The Mg 2+ concentration was 1.5 mM and the Taq polymerase 'Supertaq'. Primer set 3 required an annealing temperature of 63_C and each fragment was examined initially for point mutations by SSCP analysis.
The Applied Biosystems ABI model 373 automated sequencer was then used to: characterise the nature of the SSCP bandshifts detected; sequence both strands of the VHL coding sequence in adrenal phaeochromocytoma kindreds (group A); and to sequence the forward strand of the VHL coding region in the remaining patients (groups B and C).
The PCR products remaining after SSCP analysis and representing the VHL coding region were purified using Promega Wizard TM PCR purification columns. The purified products were ethanol precipitated, redissolved in 4.4 µl H 2 O and added to 1.6 pmol of primer and 4.0 µl of Prism TM ready reaction Dye Deoxy TM Terminator Cycle Sequencing Kit in a total volume of 10 µl. The reaction mixture was overlaid with mineral oil and cycle sequencing was performed on a Perkin Elmer Cetus Thermal Cycler for 35 cycles: 96_C 30 s, 54_C 30 s, and 60_C 4 min. Dideoxy terminated DNA fragments were ethanol precipitated before analysis using the ABI automated sequencer.
Family linkage studies with microsatellite markers linked to VHL (D3S1038 and D3S1317) were performed when a mutation could not be detected.
Analysis of GDNF.
Phaeochromocytoma tumour DNA and germline DNA from familial phaeochromocytoma patients was analysed for mutations in GDNF.
636 bp of coding sequence contained in two exons were amplified using the following two sets of primer sequences (F: 5′ ATGAAGTTATGGGATGTCGTGGC 3′, R: 5′ AGTCACTGC-TCAGCGCGAAGG 3′ and F: 5′ AAATATGCCAGGATTATC-CTGA 3′, R: 5′ CAGATACATCCACACCTTTTAGCG 3′).
Each fragment was amplified using PCR and analysed for point mutations according to Crossey et al. (33) with some minor changes: the SSCP analysis was performed at 4_C and the gels for exon 2 analysis were electrophoresed for 24 h.
The nature of the exon 2 SSCP bandshift detected was characterised using a Thermo Sequenase radiolabeled terminator cycle sequencing kit supplied by Amersham Life Science and appropriate primer sequences (F: 5′ CTTGGGTCTGGGCTAT-GAAACC 3′ and R: 5′ CTGCAGTACCTAAAAATCAGTT-CC 3′).
